Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173505 · ClinicalTrials.gov registry record · Phase 1
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06173505 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 28 participants.
The verdict
NCT06173505, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Interventions
- COMBINATION_PRODUCT Vudalimab + Carboplatin + Pemetrexed
- COMBINATION_PRODUCT Pembrolizumab + Carboplatin + Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173505
The ClinicalTrials.gov registry entry for NCT06173505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vudalimab + Carboplatin + Pemetrexed is the first listed.
NCT06173505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06173505 about?
NCT06173505 is a clinical study titled "Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC". The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in pati...
What is the current status of trial NCT06173505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-12-27. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT06173505?
The interventions under investigation include: Vudalimab + Carboplatin + Pemetrexed (COMBINATION_PRODUCT), Pembrolizumab + Carboplatin + Pemetrexed (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06173505?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.